Please assess the completion status of the following clinical trial:

Trial Title: An Open-Label Extension Study of Edasalonexent in Boys With Duchenne Muscular Dystrophy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
For Patients who Completed CAT-1004-201 or CAT-1004-301:~Inclusion Criteria:~* Written consent/assent by patient and/or legal guardian as per regional and/or Institutional Review Board (IRB)/Independent Ethics Committee (IEC) requirements~* Completion of either CAT-1004-201 or CAT-1004-301~Exclusion Criteria:~* In the Investigator's opinion, unwilling or unable for any reason to complete all study assessments and laboratory tests and comply with scheduled visits, administration of drug, and all other study procedures~For Siblings of Patients who Completed CAT-1004-201 or CAT-1004-301:~Inclusion Criteria:~* Written consent/assent by patient and/or legal guardian as per regional and/or Institutional Review Board (IRB)/Independent Ethics Committee (IEC) requirements~* A sibling of a patient who completed either CAT-1004-201 or CAT-1004-301~* Diagnosis of DMD based on a clinical phenotype with increased serum creatine kinase (CK) and documentation of mutation(s) in the dystrophin gene known to be associated with a DMD phenotype~* Followed by a doctor or medical professional who coordinates Duchenne care on a regular basis and willingness to disclose patient's study participation with medical professionals~Exclusion Criteria:~* Use of oral corticosteroids at screening; use of inhaled, intranasal, and topical corticosteroids is permitted~* Use of another investigational drug, idebenone, or dystrophin-focused therapy within 4 weeks. Exception: Patients who are currently on or plan to initiate treatment with approved oligonucleotide exon-skipping therapies, and expected to continue treatment throughout the study, will be eligible~* Use of the following within 4 weeks prior to Day 1: immunosuppressive therapy, anticoagulants, cyclosporine, dihydroergotamine, ergotamine, fentanyl, alfentanil, pimozide, quinidine, sirolimus or tacrolimus~* Use of human growth hormone within 3 months prior to Day 1~* Other prior or ongoing significant medical conditions

- Gender: MALE
- Minimum Age: 4 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- Dose 1 (Type: EXPERIMENTAL): Edasalonexent 100mg/kg/day. Capsules taken by mouth three times per day.

Based on this trial design, predict the completion outcome and termination type (if applicable).